Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 14;13(9):2078–2085. doi: 10.1080/21645515.2017.1342021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Taylor & Francis

PMC Copyright notice

Figure 3. — Glycoprotein-specific T-cell response measured by flow cytometry with intracellular cytokine staining (ICS) at different time points pre- and post-vaccination. CD4 T-cell response in all participants (A, n = 31 in the low dose group and n = 30 in the high dose group) and those with pre-existing adenovirus type-5 neutralising antibody titres ≤1:200 (B, n = 13 in the low dose group and n = 9 in the high dose group) or >1:200 (C, n = 18 in the low dose group and n = 21 in the high dose group), and CD8 T-cell response in all participants (D, n = 31 in the low dose group and n = 30 in the high dose group) and those with pre-existing adenovirus type-5 neutralising antibody titres ≤1:200 (E, n = 13 in the low dose group and n = 9 in the high dose group) or >1:200 (F, n = 18 in the low dose group and n = 21 in the high dose group). Proportions of glycoprotein-specific CD4 (G) and CD8 (H) cells that produce any combination of the three cytokines at day14 and day 28. TNF = tumour necrosis factor. IL = interleukin. IFN = interferon. Cases with undetected T cell response were not shown. The line at median with 75th percentiles (3rd quatile, Q3) were shown in the Figure.